The short version of analytical standard fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-12. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
=== Selected books === Diagnosis and Management of Renal Disease and Hypertension (1988) ISBN 9780812111293 Immunohistology in Diagnostic Pathology (1989) ISBN 9780849349874 Non-neoplastic Kidney Diseases (2005) ISBN 9781881041962 Primer on Kidney Diseases (2009) ISBN 9781416051855 Fundamentals of Renal Pathology (2013) ISBN 9783642390791 Heptinstall's Pathology of the Kidney (2024) ISBN 9781975161538
=== Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry (since 1985) === 2021 Veronica M. Bierbaum 2020 Kimberly A. Prather 2019 Jennifer S. Brodbelt 2018 Carol Vivien Robinson 2017 Vicki H. Wysocki 2015 Hilkka I. Kenttämaa 2010 Catherine E. Costello 2008 Catherine C. Fenselau 1990 Marjorie G. Horning
Epitiostanol, sold under the brand name Thiodrol, is an injected antiestrogen and anabolic–androgenic steroid (AAS) of the dihydrotestosterone (DHT) group which was described in the literature in 1965 and has been marketed in Japan as an antineoplastic agent for the treatment of breast cancer since 1977.
Some individuals with CAIS may choose to retain their gonads. If this is the case, annual imaging of the gonads via MRI or ultrasound is recommended in order to monitor for signs of malignancy. Diagnostic laparoscopy and biopsy are also to be considered if imaging is ambiguous. A study in 2012 claimed that adult women with CAIS are increasingly likely to keep their gonads due to perceived benefits. A retrospective study which includes postpubertal CAIS individuals seen at a single UK DSD center shows that there has been a temporal shift away from gonadectomy. 76.5% CAIS individuals between 2020 and 2025 elected to retain their gonads in this study. Endogenous hormone profiles show very specific features that influence bone health, hormonal replacement therapy may improve bone mineral density, but it does not normalize it. For individuals with CAIS who wish to keep their gonads, a biannual screening program is proposed. It may be possible to avoid gonadectomy throughout the patient's life with regular imaging and routine monitoring to ensure the gonads are healthy. It is emphasized that not all imaging abnormalities are indicative of malignancy. Some activists consider that cancer risk is used to legitimate surgical and hormonal intervention because intersex bodies were positioned as inherently sick and in need of modification. Research also suggest that timely intervention to reduce genotoxicity such as DNA damage, inflammation and imbalanced autophagy may promote germ cells specification and decrease the risk of germ cells tumor.
Sources: en.wikipedia.org
==== Antigonadotropic effects ==== Changes in endogenous testosterone levels may also contribute to differences in myotrophic–androgenic ratio between testosterone and synthetic AAS. AR agonists are antigonadotropic – that is, they dose-dependently suppress gonadal testosterone production and hence reduce systemic testosterone concentrations. By suppressing endogenous testosterone levels and effectively replacing AR signaling in the body with that of the exogenous AAS, the myotrophic–androgenic ratio of a given AAS may be further, dose-dependently increased, and this hence may be an additional factor contributing to the differences in myotrophic–androgenic ratio among different AAS. In addition, some AAS, such as 19-nortestosterone derivatives like nandrolone, are also potent progestogens, and activation of the progesterone receptor (PR) is antigonadotropic similarly to activation of the AR. The combination of sufficient AR and PR activation can suppress circulating testosterone levels into the castrate range in men (i.e., complete suppression of gonadal testosterone production and circulating testosterone levels decreased by about 95%). As such, combined progestogenic activity may serve to further increase the myotrophic–androgenic ratio for a given AAS.
=== Linus Pauling Institute === Robinson was the president, director, and a research professor with tenure at the institute. In June 1978, Robinson was asked to consult with the Executive Committee of the Linus Pauling Institute regarding important decisions involving the Institute. The members of the Executive Committee included Robinson, Pauling, and Executive Vice President Richard Hicks. The same day Robinson was asked to consult, he (Robinson) dismissed Hicks by terminating the fund raising services agreement employing Hicks, claiming that Hicks had failed to generate the substantial donations expected of him. Disturbed by Robinson's swift actions against Hicks, Pauling declared that he no longer had "trust and confidence in Robinson", and asked him to resign immediately. Robinson requested thirty days to consider the resignation and ultimately refused. Pauling called a meeting of the board of trustees regarding Robinson's refusal to resign. The board granted Robinson a leave of absence, and passed all executive authority to Pauling, later electing him president and director of the institute.
=== Challenges === The stigma surrounding addiction can heavily influence opioid addicts not to seek help. Stigma may arise from a variety of sources, including friends, family, employers, and healthcare providers. People who experience stigma related to their opioid use disorder are less inclined to seek out treatment or remain in treatment because of shame or feelings of being judged. Therefore, reducing stigma via education and support improves outcomes in the treatment of OUD and makes people more confident in seeking treatment. Many people view addiction as a moral failing rather than a medical condition, which can lead to feelings of shame and isolation. This stigma can affect family members, making it difficult for them to support their loved ones effectively. According to position papers on the treatment of opioid dependence published by the United Nations Office on Drugs and Crime and the World Health Organization, care providers should not treat opioid use disorder as the result of a weak moral character or will but as a medical condition. Some evidence suggests the possibility that opioid use disorders occur due to genetic or other chemical mechanisms that may be difficult to identify or change, such as dysregulation of brain circuitry involving reward and volitional experience. It has also been hypothesized that endocrine and autonomic nervous system abnormalities can be opioid-induced. Critically, the endogenous opioid system is involved in reward; changes to this system affect experience and subsequent behavior.
==== Methylnaltrexone bromide ==== Methylnaltrexone bromide is the bromide salt form of methylnaltrexone, a quaternary methyl derivative of noroxymorphone. The methyl group and the quaternary salt formation increase the polarity and reduce the lipid solubility thereby restricts the blood–brain-barrier penetration. Methylnaltrexone has eight times higher affinity for MOR than for κ-opioid receptor (KOR) and δ-opioid receptor (DOR). Naltrexone forms interaction with Asp147 and Tyr148 along with a hydrogen bond with Lys233.
Different views (also known as projections) of the chest can be obtained by changing the relative orientation of the body and the direction of the x-ray beam. The most common views are posteroanterior, anteroposterior, and lateral. In a posteroanterior (PA) view, the x-ray source is positioned so that the x-ray beam enters through the posterior (back) aspect of the chest and exits out of the anterior (front) aspect, where the beam is detected. To obtain this view, the patient stands facing a flat surface behind which is an x-ray detector. A radiation source is positioned behind the patient at a standard distance (most often 6 feet, 1,8m), and the x-ray beam is fired toward the patient. In anteroposterior (AP) views, the positions of the x-ray source and detector are reversed: the x-ray beam enters through the anterior aspect and exits through the posterior aspect of the chest. AP chest x-rays are harder to read than PA x-rays and are therefore generally reserved for situations where it is difficult for the patient to get an ordinary chest x-ray, such as when the patient is bedridden. In this situation, mobile X-ray equipment is used to obtain a lying down chest x-ray (known as a "supine film"). As a result, most supine films are also AP. Lateral views of the chest are obtained in a similar fashion as the posteroanterior views, except in the lateral view, the patient stands with both arms raised and the left side of the chest pressed against a flat surface.
Sources: en.wikipedia.org
=== Hearing loss === Hearing loss in Treacher Collins syndrome is caused by deformed structures in the outer and middle ear. The hearing loss is generally bilateral with a conductive loss of about 50–70 dB. Even in cases with normal auricles and open external auditory canals, the ossicular chain is often malformed. Attempts to surgically reconstruct the external auditory canal and improve hearing in children with TCS have not yielded positive results. Auditory rehabilitation with bone-anchored hearing aids (BAHAs) or a conventional bone conduction aid has proven preferable to surgical reconstruction.
Ketogenesis is the biochemical process through which organisms produce ketone bodies by breaking down fatty acids and ketogenic amino acids. The process supplies energy to certain organs, particularly the brain, heart and skeletal muscle, under specific scenarios including fasting, caloric restriction, sleep, or others. (In rare metabolic diseases, insufficient gluconeogenesis can cause excessive ketogenesis and hypoglycemia, which may lead to the life-threatening condition known as non-diabetic ketoacidosis.)
==== Crusader period ==== The Crusaders renamed the city Ibelin and built its castle there in 1141. An excavation led by Professor Dan Bahat in 2005 revealed the main gate. Its namesake noble family, the House of Ibelin, was important in the Kingdom of Jerusalem and later in the Kingdom of Cyprus. Salvage excavations at the west of the tell unearthed a stash of 53 Crusader coins of the 12th and 13th centuries.
=== Meiosis === When C. brunneus was exposed to X-irradiation during the zygotene-early pachytene stages of meiosis, this treatment caused a significant increase in meiotic cell chiasma frequency. Chiasma frequency was scored during the subsequent diplotene-diakinesis stages of meiosis.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.